Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Medpace was the Fund's largest contributor in H1 FY26, showing a strong inflection in fundamentals with robust net bookings growth and stronger-than-expected FY26 guidance after a period of cyclical weakness.
— Kris Webster, Michael Poulsen, and Jack McManus
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Medpace Holdings, Inc.
Medpace is a global clinical contract research organization featuring a robust balance sheet and strong cash generation. While near-term growth...
Our investments in drug development companies like Charles River Labs (CRL) and Medpace Holdings (MEDP) pulled back, driven by AI disruption fears.
Medpace posted strong Q2 results that beat expectations on both top and bottom lines, leading to a full-year guidance upgrade. Furthermore, massive share...
More institutional theses from Canopy Investors
SBAC's share price increased 29% in April. SBAC leases mobile...
Visional is positioned to benefit from Japan's structural shifts toward greater mid-career labor mobility due to shrinking demographic trends and labor shortages. Its flagship platform,...
PTC's deterministic software is essential for physical manufacturing and engineering design, making it highly insulated from AI-driven disruption. The company's deep...